Company intelligence / Profile preview
PersonGen BioTherapeutics
Suzhou, Jiangsu, Chinaen.persongen.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
PersonGen has made significant advancements in CAR-T therapies, with several products in clinical trials. They have launched the world's first clinical trials for MUC1-CAR-T and multi-target CAR-NK cell products.
- Therapeutic areas
- OncologyRheumatology
- Modalities
- CAR-T cell therapiesbispecific antibodiesUCAR-TiPSCγ-δT cells
- Industry
- Biotech
02
Drug pipeline
41 assets40 more assets in the full pipeline.
03
Partnerships
Collaborations with over 10 medical centers in China
Beyond the preview
Go deeper on PersonGen BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PersonGen BioTherapeutics.